Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5541572 | 0.99 | AGXT (0.45) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL5540447 | 0.99 | AGXT (0.45) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL5544455 | 0.95 | AGXT (0.47) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL5544267 | 0.89 | CYP2A6 (0.50) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL5537186 | 0.80 | AGXT (0.62) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL2095290 | 0.79 | AGXT (0.49) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL2089869 | 0.77 | AGXT (0.46) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL16399948 | 0.76 | CYP2A6 (0.56) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL9852785 | 0.74 | CYP2A6 (0.55) | AGXTCYP2A6ASIC3LOXL2ADRB2 | |
| SCHEMBL2096518 | 0.74 | CYP2A6 (0.55) | AGXTCYP2A6ASIC3LOXL2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | AGXT 2967/4885CYP2A6 1119/4885ASIC3 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.